Encyclopedia entry

DSIP (Delta Sleep-Inducing Peptide)

Evidence: Mixed evidence

Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)

Last updated 2026-06-04

Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.

AI-friendly summary · DSIP

DSIP is a synthetic nine-amino-acid peptide first isolated in the late 1970s from the cerebral venous blood of rabbits subjected to electrically induced sleep. The original Russian and German EEG sleep-architecture literature, mostly from the 1980s and early 1990s, reported effects on delta-wave sleep and sleep latency in human volunteers. No modern phase II or phase III randomised controlled trials have been published, the underlying mechanism remains contested, and no specific high-affinity DSIP receptor has been definitively identified.

Mechanism of action

How DSIP works

The DSIP mechanism is still poorly characterised in modern neuroscience terms. Proposed mechanisms in the older literature include thalamocortical modulation contributing to slow-wave EEG activity, indirect GABA-adjacent activity, and neuroendocrine effects on the pulsatile release of growth hormone, cortisol, and luteinising hormone. No specific high-affinity DSIP receptor has been definitively identified. Modern reviews generally describe the mechanism as unresolved and note that several reported effects have not been replicated in independent contemporary laboratories.

Source: PubMed search: DSIP delta sleep-inducing peptide (1970s to 1990s literature)

What the older literature shows

DSIP was first described by Schoenenberger and Monnier in 1977, isolated from the cerebral venous blood of rabbits in an electrical sleep-induction model. The bulk of the human literature was produced in the 1980s and early 1990s, primarily by Russian, Swiss, and German research groups. Modern publication frequency is low, independent replication of the early sleep-architecture findings in contemporary ICH-GCP trials is absent, and the compound has not progressed to any western regulatory filing.

· Early isolation work by Schoenenberger and Monnier in the late 1970s from rabbit cerebral venous blood under electrically induced sleep.
· Russian-language and German-language EEG sleep-architecture studies from the 1980s and early 1990s reporting effects on delta-wave sleep, sleep latency, and subjective sleep quality.
· Smaller strands of older literature on chronic pain modulation, alcohol-withdrawal symptoms, and neuroendocrine effects on growth hormone and cortisol pulsatility.
· Mechanistic uncertainty: no specific high-affinity DSIP receptor has been definitively identified; proposed thalamocortical and GABA-adjacent mechanisms remain contested.
· No published phase II or phase III randomised controlled trials by modern ICH-GCP standards.
· No MHRA, EMA, or FDA marketing authorisation as a medicine.

Related compounds: Selank (see Selank encyclopedia entry) and Semax (see Semax encyclopedia entry) are separate Russian-developed neuropeptides often discussed alongside DSIP in the nootropic and sleep-research adjacent literature.

UK regulatory status

DSIP sits outside the Misuse of Drugs Act 1971 and outside the Psychoactive Substances Act 2016. It has zero UK marketing authorisations as a medicine. UK retailers can sell it lawfully only by labelling it for "research use only, not for human or animal consumption" and by avoiding any therapeutic claim.

· Not a controlled drug under the Misuse of Drugs Act 1971.
· Not scheduled under the Psychoactive Substances Act 2016.
· No UK marketing authorisation as a medicine.
· No EMA or FDA marketing authorisation in the EU or US.
· Sold legally as a research chemical when marketed without health claims.
· Becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims about it.

Risks and unknowns

What the literature does not yet show about DSIP

Known concerns

The human evidence base is old, with most peer-reviewed work predating modern ICH-GCP trial standards. Independent replication in contemporary trials is absent.
The mechanism is contested. No specific high-affinity DSIP receptor has been definitively identified, which limits confidence in any reported effect.
Older neuroendocrine work suggested effects on GH, cortisol, and LH pulsatility; the long-term implications are not characterised in modern studies.
Purity of UK research-peptide supply varies. CoA gating and HPLC analysis differ between retailers.
Sleep-research peptides sit in a high E-E-A-T sensitivity area where claims of efficacy require unusually strong evidence to be lawful and ethical.

Open questions in the literature

Optimal route of administration in humans has never been formally re-studied to modern standards.
Pharmacokinetics in humans (half-life, clearance, distribution) are not well characterised by current pharmacokinetic standards.
Whether any of the older Russian or German EEG sleep-architecture findings would replicate in a contemporary blinded RCT is unknown.
Long-term effects beyond the short duration of the original studies are unknown.
Interactions with western-licensed sleep medications, sedatives, or psychiatric medications have not been formally studied.

Regulatory note

Not a controlled drug under the Misuse of Drugs Act 1971. Not scheduled under the Psychoactive Substances Act 2016. No UK marketing authorisation as a medicine. Becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims about it.

Important: PeptideClear publishes encyclopedia commentary only and does not recommend human use. Speak to a UK-registered prescriber before any medical decision.

Where to learn more

· PubMed search: DSIP delta sleep-inducing peptide returns the older Russian, German, and Swiss sleep-architecture literature.
· PubMed: Schoenenberger Monnier DSIP for the original isolation work from the late 1970s.
· Related compounds: Selank and Semax encyclopedia entries.
· Editorial stack discussion: sleep stack.
· UK retailer purity comparison: research peptides UK retailers.

Frequently asked questions

Is DSIP legal in the UK?

DSIP is not a controlled drug under the Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It is sold legally by UK research peptide retailers under "research use only, not for human or animal consumption" framing. It holds no UK marketing authorisation as a medicine.

What does the human evidence show for DSIP?

The DSIP human evidence base is dominated by older Russian and German EEG sleep-architecture studies from the late 1970s, 1980s, and early 1990s. Reported effects on delta-wave sleep, sleep latency, and subjective sleep quality have not been replicated in modern ICH-GCP randomised controlled trials. No phase II or phase III western regulatory submission has been made.

What is the regulatory status of DSIP in the UK?

DSIP has no UK marketing authorisation as a medicine and no EMA authorisation in the EU. It is sold as a research chemical when marketed without health claims. The moment a retailer, clinic, or commentator makes a therapeutic claim about DSIP it becomes an unlicensed medicinal product and the MHRA can act.

Is the DSIP mechanism understood?

The mechanism is still contested. Proposed mechanisms in the older literature include thalamocortical modulation, indirect GABA-adjacent activity, and effects on neuroendocrine pulsatile release of growth hormone and cortisol. No specific high-affinity DSIP receptor has been definitively identified, and modern neuroscience reviews generally describe the mechanism as poorly characterised.

Where can I learn more about DSIP?

A PubMed search for "DSIP delta sleep-inducing peptide" returns roughly 200 papers, the majority of which are from the 1970s to 1990s in Russian, German, or English. Modern publication frequency is low. The "Where to learn more" section above links to the primary sources.

Where to buy DSIP in the UK

Compare UK research-peptide retailers stocking DSIP, with current prices and CoA status. Research use only, not for human or animal consumption.

Compare DSIP prices

Clinical evidence record

Read the clinical evidence record for DSIP

Top peer-reviewed citations, mechanism of action, structured UK regulatory status. Machine-readable companion to this encyclopedia entry.

Popular on PeptideClear

Research peptides

BPC-157 (UK)

Collagen

Best UK collagen brands 2026

GLP-1

UK GLP-1 clinics compared

Methodology

CoA Trust Index

Shop

BPC-157 UK prices

Ready to buy

Buy DSIP in the UK

UK retailers compared by price, Trust Index, and CoA practice. Editorial commentary only. Research use only.

Buy DSIP in the UK CoA Trust Index